Mydecine Innovations Group Inc

Algernon Pharmaceuticals Inc., based in Vancouver, BC, is a clinical-stage Canadian drug development and repurposing company focused on addressing unmet global medical needs through innovative therapeutic applications. The company employs a cost-effective drug repurposing model that leverages existing compounds with known safety profiles to explore new therapeutic uses, significantly reducing the risk of failure and development time. Algernon's product pipeline includes NP251 (Repirinast), originally developed for asthma, and AP188 (NN-Dimethyltryptamine), which is being advanced for potential treatments in stroke and traumatic brain injury. The company is committed to advancing its research programs and establishing new diagnostic and treatment medical clinics, particularly for Alzheimer's disease, utilizing cutting-edge PET scan technology. Generated from the website

Zymeworks Inc., based in Vancouver, BC, is dedicated to developing novel medicines aimed at patients with difficult-to-treat diseases. The company leverages revolutionary technologies and a fully integrated R&D engine, supported by a team of world-class researchers, to discover, develop, and commercialize innovative biotherapeutics globally. Focused on addressing areas of high unmet medical need, Zymeworks strives to deliver transformational therapies for challenging cancers and other serious diseases. Their growing pipeline includes multifunctional therapeutics, bolstered by best-in-class antibody-drug conjugates and multispecific antibody therapeutic technology platforms. Generated from the website

ME Therapeutics Holdings Inc. is a preclinical biotechnology company based in Vancouver, BC, specializing in the development of novel cancer-fighting therapeutics within the field of Immuno-Oncology. The company focuses on targeting myeloid cells to directly treat cancer and enhance the effectiveness of existing Immuno-Oncology drugs, such as checkpoint inhibitors. With a proven track record in immunology related to cancer and inflammation, ME Therapeutics is committed to advancing its innovative treatment candidates, including mRNA therapies that have shown encouraging anti-cancer efficacy. The organization is actively engaged in research and development initiatives to address currently untreatable cancers through the modulation of the immune system. Generated from the website